<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Recently, we reported a high prevalence of immunoglobulin G and/or immunoglobulin M anticardiolipin antibodies (aCL) in patients with <z:e sem="disease" ids="C0400936" disease_type="Disease or Syndrome" abbrv="">autoimmune liver diseases</z:e>, namely, autoimmune <z:hpo ids='HP_0012115'>hepatitis</z:hpo> (AIH), primary <z:hpo ids='HP_0002613'>biliary cirrhosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e>), and primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp> (PSC), which were independent of the respective isotypes of antibodies against beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (anti-b2GPI) </plain></SENT>
<SENT sid="1" pm="."><plain>Immunoglobulin A (IgA) aCL and IgA anti-b2GPI are the least studied of the three specific isotypes either in <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) or in other conditions </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Therefore, we investigated the prevalence and clinical significance of IgA anti-b2GPI and IgA aCL by enzyme-linked immunosorbent assays in another set of Caucasian patients with <z:e sem="disease" ids="C0400936" disease_type="Disease or Syndrome" abbrv="">autoimmune liver diseases</z:e> (59 AIH, 96 PBC, and 37 PSC) </plain></SENT>
<SENT sid="3" pm="."><plain>The disease controls group consisted of 50 <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C virus (HCV) patients, 50 <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B virus (HBV), 30 alcoholic <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALD</z:e>), 30 non-alcoholic steatohepatitis (NASH), and 110 healthy controls </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS AND DISCUSSION: IgA anti-b2GPI prevalence was higher in AIH (50.8%) compared to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e> (p = 0.005), PSC (p = 0.008), NASH (p = 0.004), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALD</z:e> (p = 0.01), and HCV (p = 0.002) </plain></SENT>
<SENT sid="5" pm="."><plain>The titers were also significantly higher in AIH compared to any other group of the study </plain></SENT>
<SENT sid="6" pm="."><plain>IgA aCL prevalence was higher in AIH (33.9%) compared to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e> (p = 0.005), PSC (p = 0.014), NASH (p = 0.001), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALD</z:e> (p = 0.004), and HCV (p &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>IgA anti-b2GPI or IgA aCL were not associated with APS features in patients with liver <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Of note, IgA anti-b2GPI and IgA aCL were associated with clinical and biochemical markers of disease severity in AIH and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>We demonstrated a high prevalence and high titers of IgA anti-b2GPI in patients with AIH compared to any other <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> of the study </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: IgA anti-b2GPI and IgA aCL were associated with the severity and biochemical activity of AIH and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e>, but long-term prospective studies are needed to address whether this new finding is of clinical importance in AIH and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PBC</z:e> patients </plain></SENT>
</text></document>